- A. Health Biotechnology
- Areas of activity
- Therapeutic areas
- Analgesia & Pain
- Inflammatory diseases
- Ophtalmology and optometry
- Digestive system and hepatology
- Central nervous system
Sylentis focuses on researching new therapeutic approaches based on gene silencing. Sylentis is specialised in developing therapies via interference RNA, a powerful tool for rational drug design.
We are developing treatments for glaucoma and dry eye syndrome. Sylentis is also focusing on inflammatory bowel disease. Furthermore, Sylentis is focusing on post-traumatic neuron lesions and ischaemia, neurodegenerative diseases and dementia.
Because the release of RNAi in the body is an important part of these technologies, the company has a number of research projects under way regarding the controlled release of drugs, in cooperation with various public and private institutions.